Rituximab Monotherapy for EBV-HLH and CAEBV

Summary

This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV infection, to evaluate the clinical efficacy of Rituximab in the treatment of EBV-HLH and CAEBV.

Timeline

Start

2022-02-01

Primary completion

2024-02-01

Completion

2024-04-01

Drugs

Indications